Navigation Links
Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
Date:2/21/2008

eived orphan drug designation by the EMEA, which may provide it with up to ten years market exclusivity in the EU; and

- AT2220 for Pompe disease is currently in Phase 1 clinical trials.

- SPD550 (Larazotide Aceotate) for Gastro Intestinal ("GI") disorders - In December 2007 Shire licensed rights to SPD550 (also known as AT-1001), in markets outside of the US and Japan, from Alba Therapeutics Corporation ("Alba"). SPD550 is Alba's lead inhibitor of barrier dysfunction in various GI disorders and is currently in Phase 2 development for the treatment of Celiac disease.

- SPD487 (Amphetamine transdermal system ("ATS")) - ADHD - In June 2007 Shire acquired exclusive development rights to ATS following completion of early development work by Noven.

During 2007 Shire has made $155.9 million of up-front payments for the in-licensing of the above products comprising $75.0 million to Renovo, $50.0 million to Amicus, $25.0 million to Alba and $5.9 million to Noven. Shire also made a $50 million equity investment in Renovo Group plc.

Existing pipeline developments:

- VYVANSE for ADHD in adult patients

- In September 2007, the FDA accepted the filing of a supplemental New Drug Application for VYVANSE for the treatment of ADHD in adult patients. The Prescriptions Drug User Fee Act ("PDUFA") action date is April 28, 2008.

- On October 25, 2007 Shire released results from the Phase 3 clinical trials in adults. In this double-blind, placebo-controlled, four-week study with dose escalation in 414 adults aged 18 to 55 years, treatment with VYVANSE at all doses studied (30mg, 50mg, 70mg) was significantly more effective than placebo.

- Adults represent the largest and fastest growing segment of the ADHD market with a total of 9.9 million patients, of which 7.5 million are untreated.

- DAYTRANA - ADHD - Regulatory submissions were filed for approval of the product with Health Canada on November 29, 2007 and with the
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Correction Re Website
2. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
3. Shire Engages Palio
4. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
5. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
6. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire plc: Board Changes
9. David Mott Appointed Non Executive Director at Shire
10. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
11. Shire Divests Non-Core Product Portfolio to Almirall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)...  Pharmacyclics, Inc. (NASDAQ: PCYC ) ... newly developed Bruton,s tyrosine kinase (BTK) inhibitor for ... results of these preclinical evaluations have been communicated ... feedback received from the Agency is supportive of ... preclinical work is required to begin a Phase ...
(Date:2/27/2015)... The fully automated supercritical fluidic chromatography-based ... analyze up to 48 samples utilizing automatic extraction ... targets by mass spectrometry. , The Nexera ... requirements of a wide range of applications, including ... search for disease biomarkers, additives in forming polymers, ...
(Date:2/27/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) announced today ... patients and health care advocates in the United States ... Rare Disease Day is dedicated to elevating public ... special challenges faced by patients with rare diseases and ... to stand alongside patients and caregivers representing the rare ...
(Date:2/26/2015)... WOODBRIDGE, N.J. , Feb. 26, 2015 ... and its affiliated companies, Wilentz, Goldman & ... a trade secrets lawsuit against Genewiz Inc. in excess ... obtained and utilized GenScript,s trade secrets, and that it ... court entered an order denying motions for judgment notwithstanding ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... MUNDELEIN, Ill., April 22 Sysmex America, ... Medical Center,s (Canton, OH),beta studies for its ... solution, which combines the Sysmex HST-N hematology,automation ... II TURBO,Link, enables on-demand, automated diabetes testing ...
... Full Control of Belinostat, Consolidating ... Global Rights for the Product TopoTarget Acquires ... - Deal Covers a Payment of USD 26 million (DKK 122.8 ... - Webcast Conference Call to be Held 2pm CET, TopoTarget ...
... DC A new analysis by the Project ... are investing nearly twice as much as the ... potential risks of nanotechnology. The analysis also highlights ... risk-research investment figures for the U.S. , ...
Cached Biology Technology:Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution 2Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution 3Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution 4TopoTarget Successfully Buys Back Full Control of Belinostat 2TopoTarget Successfully Buys Back Full Control of Belinostat 3TopoTarget Successfully Buys Back Full Control of Belinostat 4TopoTarget Successfully Buys Back Full Control of Belinostat 5TopoTarget Successfully Buys Back Full Control of Belinostat 6TopoTarget Successfully Buys Back Full Control of Belinostat 7Europe spends nearly twice as much as US on nanotech risk research 2
(Date:2/5/2015)... 3, 2015 Despite a lack of ... such as consumer electronics, automotive, storage and telecommunication ... technology (SMT) screen printers. Innovations in electronics and ... push the adoption curve up. Meanwhile, sale volumes ... glue dispensers are indispensable in the production of ...
(Date:1/22/2015)... MELBOURNE, Fla. , Jan. 13, 2015  Today, ... wearable technology, launched its crowdfunding campaign on Fundable, ... accelerate the build of production capacity to meet ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric ... recent success of the Wocket™ smart wallet at CES 2015 in ... named as one of the "11 Hot Products at CES" in a ... CES So Far" by Newseveryday.com and "The top 10 gadgets from CES ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... University School of Medicine and University Hospitals of Cleveland announced ... to begin a study to evaluate the safety of using ... a serious form of heart disease. , The FDA has ... of the procedure. It will involve injecting bone marrow ...
... themselves by ejecting a potent inky secretion into the ... of acids. A team of researchers with the Atlanta-based ... secretion is produced from normally inert chemicals stored separately ... 16 on-line edition of the Journal of Experimental Biology, ...
... commonly prescribed drugs for breast cancer, tamoxifen, may not ... genetic variation, according to researchers at the University of ... the level of a crucial enzyme that activates tamoxifen ... researcher James Rae, Ph.D., at the University of Michigan ...
Cached Biology News:Feds give researchers ok for safety test of adult stem cells in patients with heart disease 2Sea slug mixes chemical defense before firing at predators 2Gene variation affects tamoxifen's benefit for breast cancer 2
SDS-OutT SDS Precipitation Reagent...
Designed for use with the Agencourt SprintPrep 384 kit and all MCPrep reagent kits. Used with flat bottom 96-well microplates such as deep well plates used to culture bacteria....
... plastic tray. Ideal for staining westerns and ... for multipurposes. Pour spouts in each corner ... label may be used for identification. Lid ... or shakers for staining several gels simultaneously. ...
... The Staccato Series of systems ... for today's drug discovery, genomics, proteomics ... are available in three base configurations; ... Custom Systems Series. All Staccato ...
Biology Products: